In a recent letter to the U.S. Food and Drug Administration (FDA), Public Citizen, a 350,000-member consumer advocacy group, spoke out against the apparent off-label promotion of certain sodium-glucose cotransporter 2 (SGLT2) inhibitors. The group takes issue with direct-to-consumer advertisements for five different drugs: Farxiga (dapagliflozin), Jardiance (empagliflozin), Invokana (canagliflozin), Victoza (liraglutide), and Bydureon (extended-release exenatide). According to Public Citizen, ads in print magazines and online are inappropriately ...
Consumer Advocates Speak Out against Off-Label SGLT2 Inhibitor Promotion
Posted July 24, 2015 in Product News and Recalls
New Report: SGLT2 Inhibitor Can Cause Acute Pancreatitis
Posted July 22, 2015 in Product News and Recalls
Another report about the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin (Invokana) has surfaced, this time concerning acute pancreatitis—a rare but life-threatening side effect that could result from use of the drug. A case report published by the Journal of Basic and Clinical Pharmacy demonstrates a minor incidence of acute pancreatitis in patients using Invokana. Acute pancreatitis, which involves the sudden inflammation of the pancreas, can be caused by a ...
SGLT2 Inhibitors and Ketoacidosis: What Patients Should Know
Posted July 10, 2015 in Product News and Recalls
Last month, the U.S. Food and Drug Administration (FDA) issued a safety announcement in which it warned of a possible connection between a new type of diabetes medication, called sodium-glucose cotransporter-2 (SGLT2) inhibitors, and ketoacidosis, a serious blood condition wherein the body produces too many blood acids, or ketones. Since the alert, there have been questions from patients as well as practitioners about the drugs’ ...
Health Canada Launches Safety Review of SGLT2 Inhibitors
Posted June 29, 2015 in Product News and Recalls
Health Canada, the Canadian government’s public health department, has initiated a safety review of the diabetes drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors and their link to ketoacidosis. Ketoacidosis is a serious blood condition wherein the body produces excess blood acids, or ketones. Ketoacidosis may require hospitalization and in extreme cases can cause death.
Last month, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication warning of a link between the SGLT2 ...
continue reading...FDA Issues Warning for Type-II Diabetes Medications
Posted June 3, 2015 in Product News and Recalls
Yet another warning regarding dangerous side effects associated with approved medications has been issued by the FDA.
Three specific drugs developed for the treatment of Type-II diabetes have been singled out for their capacity to cause a dangerous blood condition.
Patients taking canagliflozin, dapagliflozin, and empagliflozin should contact their doctors to discuss the possibility of ketoacidosis – a condition where the patient’s body starts producing an overabundance of blood acids. This condition can ...
continue reading...FDA: SGLT2 Inhibitors May Lead to Serious Blood Condition
Posted May 22, 2015 in Product News and Recalls
The U.S. Food and Drug Administration (FDA) has issued a Drug Safety Communication warning that the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin may result in ketoacidosis, a serious blood condition in which the body produces excess blood acids, or ketones. Ketoacidosis may require hospitalization and in extreme cases can prove fatal. The SLGT2 inhibitors are marketed under the brand names Invokana, Invokamet, Farxiga, Jardiance, Glyxambi, and Xigduo ...
